NASDAQ$ABCL
AbCellera Biologics Inc. · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Announced financial results for the second quarter of 2024.
AbCellera reported a revenue of $7.3 million, with research fees contributing $5.5 million and milestone payments contributing $1.5 million. The company's net loss was $36.9 million, or $(0.13) per share.
- ABCL635 and ABCL575 remain on track for anticipated Clinical Trial Applications (CTAs) in the second quarter of 2025.
- Disclosed three T-cell engager programs under evaluation targeting PSMA, B7-H4, and CD-19.
- The U.S. FDA cleared Abdera's Investigational New Drug (IND) application for ABD-147, and also granted it a Fast Track designation.
- Reported the start of three additional partner-initiated programs with downstreams to reach a cumulative total of 93 partner-initiated program starts with downstreams.
Headline financials
Revenue & EPS history
AbCellera · Revenue · Quarterly
$7.32M
Revenue by segment
AbCellera · $6.6M total across 2 segments · Q3 2023
- Research Fees$6.41M-14.6%97.2%
- Licensing and Royalty$186K+20.8%2.8%
Forward guidance
The company aims to submit applications for clinical trials for ABCL635 and ABCL575 in the second quarter of 2025 and has focused preclinical work on its T-cell engager platform.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2024
-0.4%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+0.2%
Avg return
30 days after
46%
11 / 24 earnings
Positive
+17.1%
Q2 2021
Best reaction
-13.9%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.2% | -21.8% | -2.9% | |
| Q4 2025 | -1.5% | +18.6% | +1.6% | |
| Q3 2025 | -13.9% | -12.4% | -21.4% | |
| Q1 2025 | +1.0% | +2.0% | +21.4% | |
| Q4 2024 | -11.3% | -18.2% | -20.9% | |
| Q3 2024 | -0.4% | -1.1% | +6.2% | |
| Q2 2024 | -4.7% | -2.9% | -12.0% | |
| Q1 2024 | -6.6% | -6.8% | -8.0% | |
| Q4 2023 | -9.9% | -8.8% | -11.8% | |
| Q3 2023 | +14.1% | +6.8% | +17.2% | |
| Q2 2023 | -13.0% | -15.1% | -19.5% | |
| Q1 2023 | -9.1% | -14.1% | +3.0% | |
| Q4 2022 | -8.3% | -12.7% | -23.8% | |
| Q3 2022 | -1.7% | +13.1% | -7.2% | |
| Q2 2022 | +13.4% | +16.3% | -3.9% | |
| Q1 2022 | -12.0% | +11.2% | +29.1% | |
| Q4 2019 | +8.1% | +9.4% | +15.5% | |
| Q4 2021 | +8.1% | +9.4% | +15.5% | |
| Q3 2020 | -7.8% | -2.0% | -5.1% | |
| Q2 2018 | +16.3% | +10.3% | +25.0% | |
| Q2 2021 | +17.1% | +8.6% | +24.3% | |
| Q1 2018 | +0.1% | -5.2% | -24.1% | |
| Q1 2021 | +3.4% | +7.4% | -15.7% | |
| Q4 2018 | +7.8% | +24.1% | +21.3% | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro